PharmaCyte Biotech, Inc. financial data

Symbol
PMCB on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
23046 Avenida De La Carlota, Suite 600, Laguna Hills, CA
State of incorporation
NV
Fiscal year end
April 30
Former names
NUVILEX, INC. (to 1/9/2015), EFOODSAFETY COM INC (to 3/17/2009)
Latest financial report
10-Q - Q2 2024 - Sep 17, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 790 % -88.6%
Debt-to-equity 56.3 % +558%
Return On Equity 75.1 %
Return On Assets 38.4 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 7.68M shares -12.5%
Common Stock, Shares, Outstanding 7.72M shares -12.1%
Entity Public Float 18.2M USD -66.4%
Common Stock, Value, Issued 2.17K USD 0%
Weighted Average Number of Shares Outstanding, Basic 7.87M shares -37.6%
Weighted Average Number of Shares Outstanding, Diluted 7.87M shares -37.6%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 0 USD
Research and Development Expense 399K USD -3.57%
General and Administrative Expense 897K USD -59.7%
Operating Income (Loss) -7.71M USD -12.6%
Nonoperating Income (Expense) 34.7M USD +3768%
Net Income (Loss) Attributable to Parent 26.9M USD
Earnings Per Share, Basic 0.64 USD/shares
Earnings Per Share, Diluted 0.64 USD/shares

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 32.6M USD -56.3%
Assets, Current 32.9M USD -56%
Intangible Assets, Net (Excluding Goodwill) 1.55M USD -56.3%
Assets 70.2M USD -12.1%
Accounts Payable, Current 554K USD -22.9%
Employee-related Liabilities, Current 135K USD -9.39%
Accrued Liabilities, Current 684K USD +42.5%
Liabilities, Current 7.47M USD +392%
Liabilities 17.2M USD -15.9%
Accumulated Other Comprehensive Income (Loss), Net of Tax -23.3K USD -3.44%
Retained Earnings (Accumulated Deficit) -92.2M USD +22.6%
Stockholders' Equity Attributable to Parent 47.7M USD +21.7%
Liabilities and Equity 70.2M USD -12.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -373K USD -209%
Net Cash Provided by (Used in) Financing Activities -10.2M USD -262%
Net Cash Provided by (Used in) Investing Activities -7M USD
Common Stock, Shares Authorized 200M shares +50%
Common Stock, Shares, Issued 21.7M shares 0%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -17.5M USD -365%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 32.6M USD -56.3%
Interest Paid, Excluding Capitalized Interest, Operating Activities 0 USD -100%
Deferred Tax Assets, Valuation Allowance 15.2M USD -6.38%
Deferred Tax Assets, Gross 15.2M USD -6.38%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent 26.9M USD
Lessee, Operating Lease, Liability, to be Paid 1.16K USD -72.8%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.16K USD -43.6%
Deferred Tax Assets, Operating Loss Carryforwards 14.4M USD -8.23%
Preferred Stock, Shares Issued 35K shares
Preferred Stock, Shares Authorized 10M shares 0%
Additional Paid in Capital 183M USD -8.01%
Preferred Stock, Shares Outstanding 35K shares
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Interest Expense 0 USD -100%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%